Arrowhead Pharmaceuticals Inc (HDP1.DU)
| Previous Close | 21.36 |
| Open | 22.45 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 22.42 - 22.91 |
| 52 Week Range | 19.09 - 37.75 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
PASADENA, Calif., May 02, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from
- Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif., April 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
- Business Wire
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
